|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01025479 |
|
Date of registration:
|
01/12/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
|
|
Scientific title:
|
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent |
|
Date of first enrolment:
|
November 2009 |
|
Target sample size:
|
829 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01025479 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Case-Only, Time Perspective: Retrospective
|
|
|
Countries of recruitment
|
|
Korea, Republic of
| | | | | | | |
|
Contacts
|
|
Name:
|
Joon Woo Bahn, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
AstraZeneca Korea |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- pathologic confirmation of prostate cancer
- patients who are taking LHRH antagonist or anti- androgen or both of them within 6
months since starting.
Exclusion Criteria:
- patients who are hard to be analysed by limitation of chart record according to
investigators'discretion
- patients who already have been registered in this study
Age minimum:
N/A
Age maximum:
N/A
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Osteoporosis
|
|
Prostate Cancer
|
|
Primary Outcome(s)
|
|
To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.
|
|
Secondary Outcome(s)
|
|
To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.
|
|
Secondary ID(s)
|
|
NIS-OKR-CAS-2009/1
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|